✦ LIBER ✦

Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma

✍ Scribed by Tsz-Kok Yau; Anne Wing-Mui Lee; Dominique Hiu-Ming Wong; Rebecca Mei-Wan Yeung; Elian Wing-Kin Chan; Wai-Tong Ng; Macy Tong; Inda Sung Soong

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 136 KB
Volume: 28
Category: Article
ISSN: 1043-3074
DOI: 10.1002/hed.20421

No coin nor oath required. For personal study only.

✦ Synopsis

Background. The purpose of this study was to evaluate the efficacy and toxicity of cisplatin plus gemcitabine as induction chemotherapy in advanced nasopharyngeal carcinoma (NPC).

Methods. Thirty-seven patients with stage IV(A-B) NPC were treated with 3 cycles of cisplatin plus gemcitabine (cisplatin 80 mg/m 2 on day 1; gemcitabine 1250 mg/m 2 on days 1 and 8) 3-weekly as induction chemotherapy, followed by another 3 cycles of concurrent cisplatin (100 mg/m 2 on day 1) 3-weekly with accelerated radiotherapy (RT) at 70 Gy in 2-Gy fractions, 6 daily fractions per week.

Results. The overall response rate to induction chemotherapy was > 90%, and side effects other than uncomplicated hematologic toxicities were uncommon. All patients completed RT, with 92% receiving 5 cycles of chemotherapy. At a median follow-up of 2.9 years, the 3-year overall survival (OS) and diseasefree survival (DFS) rates were 76% and 63%, respectively.

Conclusions. Cisplatin plus gemcitabine is a well-tolerated, effective, and convenient induction chemotherapy regimen and warrants further studies to confirm its benefit in advanced NPC.

📜 SIMILAR VOLUMES

A concurrent chemoirradiation with cispl

A concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy with ifosfamide, 5-fluorouracil, and leucovorin for stage IV nasopharyngeal carcinoma

✍ Daniel T.T. Chua; Jonathan S. T. Sham; Gordon K. H. Au 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

## Abstract ## Background. To evaluate the toxicity and efficacy of concurrent chemoirradiation with cisplatin followed by adjuvant ifosfamide, 5‐fluorouracil and leucovorin in patients with stage IVb nasopharyngeal carcinoma (NPC) ## Patients and Methods. Between October 1998 and August 2001, 3

Induction chemotherapy followed by radio

Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma : Results of a matched cohort study

✍ Fady B. Geara; Bonnie S. Glisson; Giuseppe Sanguineti; Susan L. Tucker; Adam S. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB 👁 1 views

chemotherapy in patients with

Docetaxel, cisplatin, and fluorouracil i

Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216)

✍ David J. Adelstein; James Moon; Ehab Hanna; P. G. Shankar Giri; Glenn M. Mills; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 1 views

## Abstract ## Background In an effort to optimize nonoperative therapy in patients with locoregionally advanced head and neck squamous cell cancer, the Southwest Oncology Group conducted a phase II trial combining 3‐drug taxane‐containing induction chemotherapy with accelerated fractionation/conc

Prediction of treatment outcome by cispl

Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT)

✍ Frank J.P. Hoebers; Dick Pluim; Marcel Verheij; Alfons J.M. Balm; Harry Bartelin 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 188 KB 👁 1 views

## Abstract The purpose of our study was to test the predictive value of cisplatin‐DNA adduct levels in head and neck squamous cell carcinoma (HNSCC) patients treated with cisplatin‐radiation. Patients with advanced‐stage HNSCC were treated within a randomized trial, investigating the optimal route

A phase I/II trial of neoadjuvant chemot

A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma

✍ Jean Viallet; Marc-André Brassard; Luis Souhami; Joseph Ayoub; Pierre Del Vecchi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 2 views

## BACKGROUND. Both locoregional and distant disease control remains poor in the treatment of Stage III nonsmall cell lung carcinoma (NSCLC). This trial was conducted to evaluate the tolerance and responses of patients with NSCLC given a neoadjuvant regimen of cisplatin and vinorelbine chemotherapy

Gemcitabine, paclitaxel, and cisplatin a

Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma : A phase II multicenter study

✍ Filippo De Marinis; Fabrizio Nelli; Maria Rita Migliorino; Olga Martelli; Enrico 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract ## BACKGROUND The objective of the current study was to define the activity and tolerability, as well as the influence on resectability, of the combination of gemcitabine, paclitaxel, and cisplatin (GTP) as induction chemotherapy for patients with Stage IIIA(N2) nonsmall cell lung carc